FOLH1 and neoplasm: Meanwhile, we will need to rely on other tumour- or patient-related characteristics to individualize treatment strategies, such as tumour volume (size or number and localization of positive nodes: N1 versus M1a), tumour kinetics (PSA value and doubling time, interval from primary treatment to nodal recurrence), optimal timing of PSMA- PET, risk subgroup at diagnosis, without ever forgetting the patient’s comorbidities, expectations, and preferences.